Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DVX 201

Next Previous
Drug Profile

DVX 201

Alternative Names: DVX-201

Latest Information Update: 13 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deverra Therapeutics
  • Developer Deverra Therapeutics; Duke University
  • Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; COVID 2019 infections; Myelodysplastic syndromes

Most Recent Events

  • 07 Nov 2024 Phase I trial is ongoing in COVID-2019 infections in USA (Parenteral) (Coeptis Therapeutics pipeline, November 2024)
  • 07 Nov 2024 Adverse events and efficacy data from a phase I trial in COVID-2019 infections released by Coeptis Therapeutics
  • 24 Oct 2024 Coeptis Therapeutics expands license agreement with Deverra Therapeutics to include pandemic preparedness and emergency Use

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top